Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D73TKN
|
|||
| Drug Name |
PNT-2002
|
|||
| Drug Type |
Radiopharmaceutical
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 3 | [1] | |
| Company |
POINT Biopharma
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04647526) A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH). U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.